Investor Case
Significant Global Market Opportunities
The agricultural biological sector is transforming due to the need for sustainable solutions. Bionema is poised to meet this demand with advanced biocontrol technologies that replace declining synthetic pesticides and fertilisers.
High Demand for Sustainable Products:
Increasing adoption of alternatives that deliver ease of use, efficacy, safety, cost-efficiency, and reliability.
Regulatory Disruption in Conventional Pesticides:
• Stringent regulations and scrutiny leading to significant disruptions in the conventional market.
• Key product withdrawals are leaving growers with lower yields and declining productivity.
Faster, Cost-Effective Market Entry for Biopesticides:
• Conventional chemicals: 10 – 12 years and >£250 million development cost.
• Biopesticides: 2 – 8 years and £3 – 7 million, offering significant cost and time advantages.
Unmet Market Need:
Biopesticides fill a growing void, enabling higher yields, healthier crops, and increased nutraceutical content while addressing government-mandated sustainability goals.
Over 40 Proprietary Technologies:
• 10 technologies at advanced development stages, including bioinsecticides, biofungicides, molluscicides, bioherbicides and biofilm-producing biofertilisers.
• 2 technologies progressing through global registration for commercial launch.
Proven Market Validation:
Adoption by farmers and industry partners demonstrates technology efficacy and scalability.
Strong Development Pipeline
Bionema has an impressive portfolio of innovations aimed at addressing various agricultural challenges.
Unique Technology Platforms: Incapsulex®
Bionema’s patented Incapsulex® technology sets a new benchmark in biocontrol innovation, delivering superior performance while addressing sustainability goals.
Exclusive Patented Platform:
Biodegradable microencapsulation for controlled release of active ingredients.
Proven Efficacy:
30–40% higher performance than conventional pesticides and biopesticides.
Residue-Free Advantage:
Products enable residue-free crops, opening premium export markets.
Market Versatility:
Expansive application across biocontrol agents, biostimulants, and biofertilisers.
Commercial Validation:
Supported by strong partnerships and successful farmer trials.
Global Market Expansion:
Strategic growth into high-value territories with increasing applications for critical crops.
Strong Industry Partnerships:
Partnerships with established industry leaders, supported by significant partner investments.
Case Studies of Success:
Early customers' adoption has led to measurable improvements in crop productivity and pest control.
Technology/Product acquisition:
Syngenta acquired two of Bionema's innovative biocontrol technologies, demonstrating their commercial viability, market demand, and the company’s capability to develop cutting-edge solutions for sustainable agriculture.
Clear Commercial
Progress
Bionema is executing a robust commercialisation strategy with measurable success:
Scalable Infrastructure and Supply Chain
Bionema is ready to expand its production and delivery capabilities to meet increasing market demand.
Scalable Manufacturing:
Flexible and cost-efficient production facilities with capacity to support rapid expansion.
Quality Assurance:
Rigorous quality control processes to ensure consistency and efficacy.
Distribution Network:
Strengthening relationships with distributors and partners for effective market penetration.
Exceptional Leadership:
• Professor Dylan Jones-Evans OBE, Chairman, brings expertise in investment, business development, and finance.
• Dr Minshad Ansari, CEO and founder, has 25 years of experience as a global biocontrol expert and public speaker.
• Stephen Ford, CTO, a global entrepreneur in biopesticide development with 25 years of experience
• Both CEO and CTO responsible for £18 million in technology exits
Technical Expertise:
In-house team with strengths in strain selection, formulation, metabolomics, and delivery technologies.
Collaborative Approach:
Strong relationships with academic institutions, industry partners, and regulatory bodies.
Skilled And Experienced Team
Bionema’s leadership team combines deep industry expertise with a proven track record in innovation and commercialisation.
Trajectory Of Financial Growth
Bionema is set to achieve significant financial growth, backed by a robust market presence and increasing opportunities.
Revenue Projections:
Targeting £90 million annual revenue within 5 years, driven by global expansion and increasing product adoption.
Profitability Timeline:
Expecting positive cash flow within 3–5 years.
Valuation Growth:
• Current technology valuation: ~£30 million.
• Projected company valuation: £500 million within 5–10 years.
Investment Utilization:
Funds will be allocated to:
• Accelerating regulatory approvals.
• Expanding production capacity.
• Scaling global sales and marketing efforts.
• Further R&D for next-generation biocontrol solutions.
